Treatment of refractory and recurrent Clostridium difficile infection

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 6, 2011, Pages 330-339

  Surawicz, Christina M ^a   Alexander, Jacob ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; CB 183315; FIDAXOMICIN; FUSIDIC ACID; IMMUNOGLOBULIN; KEFIR; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; RAMOPLANIN; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENTERITIS; FECAL MICROBIOTA TRANSPLANT; FECES MICROFLORA; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; TRANSPLANTATION;

EID: 85027958654     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.59     Document Type: Review

References (105)

1. Archibald, L. K., Banerjee, S. N. & Jarvis, W. R. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J. Infect. Dis. 189, 1585-1589 (2004). (Pubitemid 38648285)
2. McDonald, L. C., Owings, M. & Jernigan, D. B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis. 12, 409-415 (2006).
3. Warny, M., Vaerman, J. P., Avesani, V. & Delmée, M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 62, 384-389 (1994). (Pubitemid 24033753)
4. Privitera, G., et al. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob. Agents Chemother. 35, 208-210 (1991).
5. Ticehurst, J. R., et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J. Clin. Microbiol. 44, 1145-1149 (2006).
6. Larson, A. M., Fung, A. M. & Fang, F. C. Evaluation of tcbB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J. Clin. Microbiol. 48, 124-130 (2010).
7. Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. & Davis, M. B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45, 302-307 (2007). (Pubitemid 47101025)
8. Cohen, S. H., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31, 431-455 (2010).
9. Nair, S., Yadav, D., Corpuz, M. & Pitchumoni, C. S. Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am. J. Gastroenterol. 93, 1873-1876 (1998). (Pubitemid 29071697)
10. Burdon, D. W., et al. Antibiotic susceptibility of Clostridium difficile. J. Antimicrob. Chemother. 5, 307-310 (1979). (Pubitemid 9210544)
11. Shuttleworth, R., Taylor, M. & Jones, D. M. Antimicrobial susceptibilities of Clostridium difficile. J. Clin. Pathol. 33, 1002-1005 (1980). (Pubitemid 10011214)
12. Nelson, R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database of Systematic Reviews, Issue 3, Art. No.: CD004610. doi:10.1002/14651858.CD004610.pub3 (2007). (Pubitemid 351805429)
13. Baines, S. D., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J. Antimicrob. Chemother. 62, 1046-1052 (2008).
14. Peláez, T., et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin. Microbiol. 46, 3028-3032 (2008).
15. Musher, D. M., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40, 1586-1590 (2005). (Pubitemid 40720807)
16. Pepin, J., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40, 1591-1597 (2005). (Pubitemid 40720808)
17. Aslam, S., Hamill, R. J. & Musher, D. M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 5, 549-557 (2005). (Pubitemid 41196754)
18. Wong, S. S., Woo, P. C., Luk, W. K. & Yuen, K. Y. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn. Microbiol. Infect. Dis. 34, 1-6 (1999). (Pubitemid 29216929)
19. Marchese, A., Salerno, A., Pesce, A., Debbia, E. A. & Schito, G. C. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 46, 253-266 (2000). (Pubitemid 30428839)
20. Jamal, W. Y., Mokaddas, E. M., Verghese, T. L. & Rotimi, V. O. In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int. J. Antimicrob. Agents 20, 270-274 (2002). (Pubitemid 35246376)
21. Peláez, T., et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46, 1647-1650 (2002). (Pubitemid 34535177)
22. Tedesco, F., Markham, R., Gurwith, M., Christie, D. & Bartlett, J. G. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet 2, 226-228 (1978). (Pubitemid 8400351)
23. Al-Nassir, W. N., et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin. Infect. Dis. 47, 56-62 (2008). (Pubitemid 351920588)
24. Louie, T. J., et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 43, 411-420 (2006). (Pubitemid 44157147)
25. Louie, T. J., et al. Results of a phase III study comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD) [abstract K-4259]. In Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ASM Press, Washington, D. C., 2007).
26. Apisarnthanarak, A., Razavi, B. & Mundy, L. M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin. Infect. Dis. 35, 690-696 (2002). (Pubitemid 35024729)
27. Young, G. P., et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 89, 1038-1045 (1985). (Pubitemid 16231567)
28. Dudley, M. N., et al. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch. Intern. Med. 146, 1101-1104 (1986). (Pubitemid 16042154)
29. de Lalla, F., et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob. Agents Chemother. 36, 2192-2196 (1992).
30. de Lalla, F., et al. Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob. Agents Chemother. 33, 1125-1127 (1989). (Pubitemid 19168680)
31. Wullt, M. & Odenholt, I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J. Antimicrob. Chemother. 54, 211-216 (2004).
32. Wenisch, C., Parschalk, B., Hasenhündl, M., Hirschl, A. M. & Graninger, W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 22, 813-818 (1996). (Pubitemid 26255600)
33. Musher, D. M., Logan, N., Bressler, A. M., Johnson, D. P. & Rossignol, J. F. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin. Infect. Dis. 48, e41-e46 (2009).
34. Musher, D. M., et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J. Antimicrob. Chemother. 59, 705-710 (2007). (Pubitemid 47073405)
35. Garey, K. W., Salazar, M., Shah, D., Rodrigue, R. & DuPont, H. I. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann. Pharmacother. 42, 827-835 (2008). (Pubitemid 351778089)
36. Basu, P. P., et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap. Adv. Gastroenterol. 414, 221-225 (2010).
37. Herpers, B. L., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin. Infect. Dis. 48, 1732-1735 (2009).
38. Lu, C. L., Liu, C. Y., Huang, Y. T., Wang, H. P. & Hsueh, P. R. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int. J. Antimicrob. Agents 35, 311-312 (2010).
39. Kopterides, P., et al. Failure of tigecycline to treat severe Clostridium difficile. Anaesth. Intensive Care 38, 755-758 (2010).
40. Salcedo, J., et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41, 366-370 (1997). (Pubitemid 27428197)
41. McPherson, S., Rees, C. J., Ellis, R., Soo, S. & Panter, S. J. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis. Colon Rectum 49, 640-645 (2006). (Pubitemid 43723812)
42. Juang, P., et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am. J. Infect. Control 35, 131-137 (2007). (Pubitemid 46283599)
43. Abougergi, M. S., Broor, A., Cui, W. & Jaar, B. G. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J. Hosp. Med. 5, E1-E9 (2010).
44. OHoro, J. & Safdar, N. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int. J. Infect. Dis. 13, 663-667 (2009).
45. Abougergi, M. S. & Kwon, J. H. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig. Dis. Sci. 56, 19-26 (2011).
46. Khoruts, A., Dicksved, J., Jansson, J. K. & Sadowsky, M. J. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J. Clin. Gastroenterol. 44, 354-360 (2010).
47. Eiseman, B., Silen, W., Bascom, G. S. & Kauvar, A. J. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44, 854-859 (1958).
48. Bowden, T. A. Jr, Mansberger, A. R. Jr & Lykins, L. E. Pseudomembranous enterocolitis: mechanism for restoring floral homeostasis. Am. Surg. 47, 178-183 (1981). (Pubitemid 11098755)
49. You, D. M., Franzos, M. A. & Holman, R. P. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann. Intern. Med. 148, 632-633 (2008). (Pubitemid 351669152)
50. Koo, H. L., Koo, D. C., Musher, D. M. & DuPont, H. L. Antimotility agents for treatment of Clostridium difficile diarrhea and colitis. Clin. Infect. Dis. 48, 598-605 (2009).
51. Dallal, R. M., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complication. Ann. Surg. 235, 363-372 (2002). (Pubitemid 34183887)
52. Koss, K., et al. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 8, 149-154 (2006). (Pubitemid 43372465)
53. Lamontagne, F., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann. Surg. 245, 267-272 (2007). (Pubitemid 46148486)
54. Dudukgian, H., Sie, E., Gonzalez-Ruiz, C., Etzioni, D. A. & Kaiser, A. M. C. difficile colitis-predictors of fatal outcome. J. Gastrointest. Surg. 14, 315-322 (2010).
55. Seder, C. W., et al. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. Am. J. Surg. 197, 302-307 (2009).
56. Al-Abed, Y. A., Gray, E. A. & Rothnie, N. D. Outcomes of emergency colectomy for fulminant Clostridium difficile colitis. Surgeon 8, 330-333 (2010).
57. Butala, P. & Divino, C. M. Surgical aspects of fulminant Clostridium difficile colitis. Am. J. Surg. 200, 131-135 (2010).
58. Ananthakrishnan, A. N. & Binion, D. G. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 4, 589-600 (2010).
59. Issa, M., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5, 345-351 (2007). (Pubitemid 46401531)
60. Rodemann, J. F., Dubberke, E. R., Reske, K. A., Seo da, H. & Stone, C. D. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5, 339-344 (2007). (Pubitemid 46401530)
61. Ananthakrishnan, A. N. & Binion, D. G. Clostridium difficile and inflammatory bowel disease: more questions than answers? Inflamm. Bowel Dis. 16, 1445-1446 (2010).
62. Das, R., Feuerstadt, P. F. & Brandt, L. J. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am. J. Gastroenterol. 105, 2040-2049 (2010).
63. McFarland, L. V., et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 20: 43-50 (1999).
64. McFarland, L. V. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 40-48 (2008).
65. McFarland, L. V., et al. Possible role of cross transmission between neonates and mothers with recurrent Clostridium difficile infections. Am. J. Infect. Control 27: 301-303 (1999). (Pubitemid 29277963)
66. Johnson, S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J. Infect. 58, 403-410 (2009).
67. Hu, M. Y., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136, 1206-1214 (2009).
68. Cadena, J., et al. Clinical predictors and risk factors for relapsing Clostridium difficile infection. Am. J. Med. Sci. 339, 350-355 (2010).
69. Kyne, L., Warny, M., Qumar, A. & Kelly, C. P. Association between antibody response in toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357, 189-193 (2001). (Pubitemid 32108091)
70. Surawicz, C. M. Treatment of recurrent Clostridium difficile infection-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 1, 32-38 (2004). (Pubitemid 40823691)
71. McFarland, L. V., Elmer, G. W. & Surawicz, C. M. Breaking the cycle: treatment strategies for 163 cases of recurrent C. difficile disease. Am. J. Gastroenterol. 97: 1769-1775 (2002). (Pubitemid 34761404)
72. Johnson, S., Schriever, C., Galang, M., Kelly, C. P. & Gerding, D. N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44, 846-848 (2007). (Pubitemid 46365312)
73. Johnson, S., et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 15, 290-291 (2009).
74. Neff, G., Zacharias, V., Kaiser, T. E., Gaddis, A. & Kemmer, N. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series. Liver Transpl. 16, 960-963 (2010).
75. Garey, K. W., Jiang, Z. D., Bellard, A. & DuPont, H. L. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J. Clin. Gastroenterol. 43, 91-93 (2009).
76. Louie, T. J., Emery, J., Krulicki, W., Byrne, B. & Mah, M. OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob. Agents Chemother. 53, 261-263 (2009).
77. Sullivan, K. M. & Spooner, L. M. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection. Ann. Pharmacother. 44, 352-359 (2010).
78. Tannock, G. W., et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156, 3354-3359 (2010).
79. McFarland, L. V., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271, 1913-1918 (1994). (Pubitemid 24177098)
80. Surawicz, C. M., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 31, 1012-1017 (2000). (Pubitemid 32299362)
81. Wullt, M., Gagslatt, M. L. & Odenhold, I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhea: a double-blind placebo-controlled trial. Scand. J. Infect. Dis. 35, 365-367 (2003). (Pubitemid 37038627)
82. Pochapin, M. The effect of probiotics on Clostridium difficile diarrhea. Am. J. Gastroenterol. 95 (Suppl. 1), S11-S13 (2000). (Pubitemid 30039352)
83. Lawrence, S. J., Korzenik, J. R. & Mundy, L. M. Probiotics for recurrent Clostridium difficile disease. J. Med. Microbiol. 54, 905-906 (2005). (Pubitemid 41216291)
84. Bakken, J. S. Resolution of Clostridium difficile-associated diarrhea using staggered antibiotic withdrawal and kefir. Minn. Med. 92, 38-40 (2009).
85. Liong, M. T. Safety of probiotics: translocation and infection. Nutr. Rev. 66, 192-202 (2008).
86. Seal, D., et al. Treatment of relapsing Clostridium difficile diarrhea by administration of a non-toxigenic strain. Eur. J. Clin. Microbiol. 6, 51-53 (1987). (Pubitemid 17034620)
87. Schwan, A., Sjolin, S., Trottestam, U. & Aronsson, B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet 2, 845 (1983).
88. Tvede, M. & Rask-Madsen, J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet 1, 1156-1160 (1989). (Pubitemid 19138849)
89. Silverman, M. S., Davis, I. & Pillai, D. R. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 8, 471-473 (2010).
90. Rohlke, F., Surawicz, C. M. & Stollman, N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J. Clin. Gastroenterol. 44, 567-570 (2010).
91. Yoon, S. S. & Brandt, L. J. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J. Clin. Gastroenterol. 44, 562-566 (2010).
92. Aas, J., Gessert, C. E. & Bakken, J. S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin. Infect. Dis. 36, 580-586 (2003).
93. MacConnachie, A. A., Fox, R., Kennedy, D. R. & Seaton, R. A. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 102, 781-784 (2009).
94. Bakken, J. S. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 15, 285-289 (2009).
95. Khoruts, A. & Sadowsky, M. J. Therapeutic transplantation of the distal gut microbiota. Mucosal Immunol. 4, 4-7 (2011).
96. van Nood, E., Speelman, P., Kuijper, E. J. & Keller, J. J. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Eur. Surveill. 14, 19316 (2009).
97. Van Dissel, J. T., et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea preclinical and preliminary clinical data. J. Med. Microbiol. 54, 197-205 (2005). (Pubitemid 40868008)
98. Mattila, E., et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand. J. Infect. Dis. 40, 702-708 (2008).
99. Sougioultzis, S., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128, 764-770 (2005). (Pubitemid 40585378)
100. Wilcox, W. H. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J. Antimicrob. Chemother. 53, 882-884 (2004).
101. Beales, I. L. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 51, 456 (2002).
102. Lowy, I., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362, 197-205 (2010).
103. Gerding, D. N. & Johnson, S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin. Infect. Dis. 51, 1306-1313 (2010).
104. Pépin, J. Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic? Clin. Infect. Dis. 46, 1493-1498 (2008). (Pubitemid 351706728)
105. Pépin, J., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171, 466-472 (2004). (Pubitemid 39179608)